Table 1.

Trial Characteristics

Trial	N	Year Closed	Study Agents	Disease Assessment Schedule
				During Treatment	Post Treatment
NSCLC
N0022	46	2002	oral vinorelbine	every 8 weeks	every 3 months
N0026	132	2003	gemcitabine, pemetrexed disodium	every 6 weeks	every 6 months
N0222	47	2006	paclitaxel, carboplatin, gefitinib	every 8 weeks	every 3 months
N0323	52	2006	temsirolimus	every 8 weeks	every 6 months
N0326	25	2006	sorafenib	every 8 weeks	every 6 months
N0426	48	2007	pemetrexed disodium, bevacizumab	every 6 weeks	every 6 months
N0528	93	2008	cedirinib, gemcitabine, carboplatin	every 6 weeks	every 6 months
N0626	110	2010	pemetrexed, sorafenib	every 6 weeks	every 3, then 6 months
N0821	65	2010	pemextrexed, carboplatin, bevacizumab	every 6 weeks	every 3, then 6 months
N9921	42	2005	carboplatin, paclitaxel	every 8 weeks	every 3 months
S0027	57	2003	vinorelbine, docetaxel	every 10 weeks	every 3, then 6 months
S0339	53	2004	gemcitabine, carboplatin, bortezomib	every 6 weeks	every 6 months
S0341	55	2005	erlotinib	every 6 weeks	every 3, then 6 months
S0342	132	2005	carboplatin, paclitaxel, cetuximab	every 6 weeks	every 3, then 6 months
SCLC
N0027	26	2003	topotecan, carboplatin, G-CSF	every 6 weeks	every 3, then 6 months
N0124	21	2004	imatinib mesylate	every 8 weeks	every 3, then 6 months
N0423	46	2008	pemetrexed disodium, carboplatin	every 6 weeks	every 6 months
N0621	23	2008	saracatinib	every 6 weeks	every 3 months
S0119	31	2003	gemcitabine, irinotecan	every 6 weeks	every 6 months
S0327	42	2004	bortezomib	every 6 weeks	every 3 months
S0435	58	2007	sorafenib	every 8 weeks	every 3 months